On A Roll: Gilead's Top-Line Quad Data Stack Up To Atripla
This article was originally published in The Pink Sheet Daily
Executive Summary
After announcing FDA approval of a new HIV combination last week, Gilead released positive comparative data on the Quad pill Aug. 15.